Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, Miller MA. 2004. Influenza and the winter increase in mortality in the United States, 1959–1999. Am J Epidemiol 160:492–502.


Sacks FM. 2004. High-intensity statin treatment for coronary heart disease. JAMA 291:1132–1134.

Schoch-Spana M. 2000. Implications of pandemic influenza for bioterrorism response. Clinical Infectious Diseases 31:1409–1413. [Online]. Available: http://www.wipo.int.

Smorodintsev AA, Karpuhin GI, Zlydnikov DM, Malyseva AM, Svecova EG, Burov SA, Hramcova LM, Romanov JA, Taros LJ, Ivannikov JG, Novoselov SD. 1970. The prophylactic effectiveness of amantadine hydrochloride in an epidemic of Hong Kong influenza in Leningrad in 1969. Bull WHO 42:865–872.

Stilianakis NI, Perelson AS, Hayden FG. 1998. Emergence of drug resistance during an influenza epidemic: Insights from a mathematical model. J Infect Dis 177:863–873.

Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, Xu X, Lu X, Katz J, Cox N, Matsuoka Y. 2003. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305:192–200.


Tisdale M. 2000. Monitoring of viral susceptibility: New challenges with the development of influenza NA inhibitors. Rev Med Virol 10:45–55.

Topol EJ. 2004. Intensive statin therapy—a sea change in cardiovascular prevention. N Engl J Med 350:1562–1564.

Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG. 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. U.S. Oral Neuraminidase Study Group. JAMA 283:1016–1024.


VanVoris LP, Betts RF, Hayden FG, Christmas WA, Douglas RGJ. 1981. Successful treatment of naturally occurring influenza A/USSR/77 HIN1. JAMA 245:1128–1131.


Walker JB, Hussey EK, Treanor JJ, Montalvo A, Hayden FG. 1997. Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza. J Infect Dis 176:1417–1422.

Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, McClain-Moss LR, Peiris JS, Rehg JE, Tuomanen EI, Webster RG. 2004. Responsiveness to a pandemic alert: Use of reverse genetics for rapid development of influenza vaccines. Lancet 363:1099–1103.

Welliver R, Manto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Huson L, Ward P, Oxford JS. 2001. Effectiveness of oseltamivir in preventing influenza in household contacts. JAMA 285:748–754.

Whitley RJ, Hayden FG, Reisinger K, Young N, Dutkowski R, Ipe D, Mills RG, Ward P. 2001. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20:127–133.

WHO (World Health Organization). 2004 (April 27). WHO Consultation on Priority Public Health Interventions Before and During an Influenza Pandemic. [Online]. Available: http://www.who.int/csr/disease/avian_influenza/guidelines/pandemicconsultation/en/ [accessed December 17, 2004].

Wood JM. 2001. Developing vaccines against pandemic influenza. Philos Trans R Soc Lond B Biol Sci 356:1953–1960.

Wood JM, Lewandowski RA. 2003. The influenza vaccine licensing process. Vaccine 21:1786–1788.


Ziegler T, Hemphill ML, Ziegler ML, Perez-Oronoz G, Klimov AI, Hampson AW, Regnery HL, Cox NJ. 1999. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis 180:935–939.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement